Abstract
Antibody-drug conjugates (ADCs), cytotoxic drugs chemically linked to antibodies, provide a means to increase the effectiveness of chemotherapy by targeting the drug to neoplastic cells. Anti-CD138 ADCs show promising preclinical efficacy for the treatment of multiple myeloma; however, the safety aspects of targeting CD138 have yet to be explored.
MeSH terms
-
Animals
-
Antibodies, Monoclonal / therapeutic use*
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Agents / toxicity
-
Disease Models, Animal
-
Immunotoxins / immunology
-
Immunotoxins / therapeutic use*
-
Mice
-
Mice, SCID
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / immunology
-
Syndecan-1 / antagonists & inhibitors*
-
Syndecan-1 / immunology
-
Xenograft Model Antitumor Assays
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents
-
Immunotoxins
-
Syndecan-1